🔗 Share this article

Given that the United States undertakes historic revisions to its immunization guidelines, one figure appears somewhat surprisingly: Høeg, a Danish American sports physician and epidemiologist who first made her name by casting doubt on Covid vaccines in the global health crisis and has zeroed in on potential deaths following Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Program

Public health authorities planned to reveal sweeping changes to the pediatric vaccination calendar recently, synchronizing the US with the Danish national calendar, it is understood – a substantial departure that would put the US out of alignment with a large portion of the global community with insufficient data for benefit. This reveal has been pushed back until the next year.

In place of Vinay Prasad, Dr. Høeg is scheduled to speak at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the agency – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

The new acting director has often pushed for ending specific childhood immunization guidelines in the US to become more similar to Denmark, a nation with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

To date statements, she has kept her attention on vaccines – usually the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Background

The appointee has little discernible background in pharmaceutical research, oversight or management, which has been typical for previous directors of the CBER. She has served at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the CDER, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Former directors of the center would “grasp laws and regulations and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Clearly, she lacks the kind of background that prior appointees who headed the center have had.”

CDER has an enormous workload at the agency, she emphasized.

“The public just zeroes in on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and every single one need to be looked after,” she noted. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant administrative component to the job, which oversees more than 5,000 personnel. “It is a huge leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment represents more teamwork among FDA leaders on immunizations, a representative said that the “inquiries rely on flawed assumptions”.

“This background aligns with the functions of her role,” the representative said, noting the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the agency head's recently launched priority voucher program, a controversial one-day drug-approval program that reportedly concerned her predecessors. “How are these drugs being selected for this fast-track system? Who is making the choices?” Dr. Howard said. “There is a lot of lack of transparency occurring at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards less stringent oversight of pharmaceuticals, aside from shots.”

Public Past Work on Immunizations

With immunizations, Høeg has a more established, if concerning, history, critics said. She authored a research paper using unverified volunteer-provided data to estimate the incidence of myocarditis after COVID-19 vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccinations are more dangerous than they are.

Among her “wish list” for the current administration encompassed revising guidelines for new vaccines and discontinuing “non-essential” immunizations, she remarked post-election on a audio program. At the agency, Dr. Høeg has allegedly suggested preventing teenage boys from obtaining COVID-19 vaccines.

“She is an complete dogmatist who begins with her beliefs and reverse-engineers to accommodate the science in a highly deceptive, untruthful fashion,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg became part of other contrarians, {like|